IDO Antibody | 36-228

IDO Antibody | 36-228 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human

Homology: N/A

Immunogen: Recombinant human IDO.

Research Area: Cancer, Immunology, Innate Immunity, Obesity

Tested Application: E, Flow, ICC, WB

Application: ELISA: (direct and indirect: 1:2, 000-1:10, 000) . Flow Cytometry: (1:200-1:500) . Immunocytochemistry: (1:500) . Western Blot: (1:2, 000-1:5, 000 using ECL; suggested blocking and dilution buffer is PBST containing 0.05% Tween 20 and 5% skim milk; suggested incubation time is 1 hour at room temperature) . Optimal conditions must be determined individually for each application.

Specificiy: Recognizes human IDO. Detects a band of ~45kDa by Western blot.

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: N/A

Clonality: Polyclonal

Clone: N/A

Isotype: N/A

Conjugate: Unconjugated

Physical State: Liquid

Buffer: Liquid. 0.2um-filtered solution in PBS, pH 7.4. Contains no preservatives.

Concentration: 1 mg/ml

Storage Condition: Stable for at least 6 months after receipt when stored at -20˚C.

Alternate Name: Indoleamine 2, 3-dioxygenase; INDO

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: IDO catalyzes the first and rate-limiting step in the main pathway of human tryptophan catabolism, the kynurenine pathway. Proinflammatory mediators, such as endotoxin and IFN-gamma induce the expression of IDO in several tissues. IDO-dependent suppression of T-cell responses might function as natural immunoregulatory mechanism. Physiological IDO activity has been implicated in T-cell tolerance to tumors, dysfunctional selftolerance in non-obese diabetic (NOD) mice, and as a protective negative regulator in autoimmune disorders.